NCT04795479View on ClinicalTrials.gov

T/QT Study to Investigate the Effect of Relacorilant on Cardiac Repolarization in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 22, 2021

Primary Completion Date

May 17, 2021

Study Completion Date

July 13, 2021

Conditions
Healthy
Interventions
DRUG

Relacorilant

Relacorilant 400 mg (therapeutic dose) or 800 mg (supra-therapeutic dose) capsule by mouth once daily

DRUG

Placebo to relacorilant

Placebo to relacorilant capsule by mouth once daily

DRUG

Moxifloxacin

Moxifloxacin 400 mg tablet by mouth

Trial Locations (1)

65802

Single Site, Springfield

Sponsors
All Listed Sponsors
lead

Corcept Therapeutics

INDUSTRY